Kyverna Therapeutics, Inc. Common Stock (KYTX)vsRegeneron Pharmaceuticals Inc (REGN)
KYTX
Kyverna Therapeutics, Inc. Common Stock
$5.16
-1.15%
HEALTHCARE · Cap: $333.34M
REGN
Regeneron Pharmaceuticals Inc
$973.36
+1.26%
HEALTHCARE · Cap: $95.99B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 28.5% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 78/100 (B+).
KYTX
Avoid28
out of 100
Grade: F
REGN
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for KYTX.
Margin of Safety
+38.3%
Fair Value
$1504.34
Current Price
$973.36
$530.98 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 40.5%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : KYTX
The strongest argument for KYTX centers on Debt/Equity, Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 40.5%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : KYTX
The primary concerns for KYTX are Revenue Growth, EPS Growth, Market Cap.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
KYTX profiles as a value stock while REGN is a growth play — different risk/reward profiles.
KYTX carries more volatility with a beta of 2.06 — expect wider price swings.
REGN is growing revenue faster at 36.3% — sustainability is the question.
REGN generates stronger free cash flow (334M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (78/100 vs 28/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Kyverna Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Kyverna Therapeutics, Inc. is an innovative biotechnology company focused on advancing immunotherapies for autoimmune diseases and other significant health challenges. Employing its proprietary genetically engineered T-cell technology, Kyverna aims to enhance the functionality of the immune system, offering specialized cellular therapies designed to improve patient outcomes substantially. With its commitment to developing cutting-edge therapeutic solutions and its strategic positioning within the growing biopharmaceutical sector, the company presents an appealing opportunity for institutional investors interested in the transformative potential of immunotherapy.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?